Author

Robert F. Roscigno

Observed names: R F Roscigno, R ROSCIGNO, R Roscigno, R.F. Roscigno, Robert F Roscigno

Institution: Gossamer Bio (United States)

Observed institutions: Duke University, Princeton University, Cold Spring Harbor Laboratory, Gossamer Bio (United States), Duke Medical Center

OpenAlex ID: A5033580792

SR proteins escort the U4/U6.U5 tri-snRNP to the spliceosome.

1995 · R F Roscigno, M A Garcia-Blanco · PubMed · 165

A mutational analysis of the polypyrimidine tract of introns. Effects of sequence differences in pyrimidine tracts on splicing

1993 · R.F. Roscigno, M. Weiner, et al. · Journal of Biological Chemistry · 147

RNA Binding by Sxl Proteins in Vitro and in Vivo

1994 · M E Samuels, D Bopp, et al. · Molecular and Cellular Biology · 101

Identification of two distinct intron elements involved in alternative splicing of beta-tropomyosin pre-mRNA.

1990 · D M Helfman, R F Roscigno, et al. · Genes & Development · 91

Seralutinib in adults with pulmonary arterial hypertension (TORREY): a randomised, double-blind, placebo-controlled phase 2 trial

2024 · Robert P Frantz, Vallerie V McLaughlin, et al. · The Lancet Respiratory Medicine · 70

530 Safety and efficacy of treprostinil in cirrhosis-related pulmonary arterial hypertension

2003 · R BENZA, J TALLAJ, et al. · Hepatology · 6

Seralutinib for the Treatment of Pulmonary Arterial Hypertension in Adults: TORREY Open-Label Extension Study

2025 · Olivier Sitbon, Sandeep Sahay, et al. · Advances in Therapy · 1

Sustained effect of seralutinib on circulating biomarkers: Lessons from the TORREY phase 2 open-label extension study

2024 · Robin Osterhout, Anna R. Hemnes, et al. · 1

A19-10 Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 3 PROSERA Trial

2026 · H A Ghofrani, V V Mclaughlin, et al. · American Journal of Respiratory and Critical Care Medicine

Interim Results from the Phase 1B and Phase 2 TORREY Open-label Extension Study of Seralutinib in Pulmonary Arterial Hypertension (PAH)

2025 · H Ghofrani, S Sahay, et al. · Pneumologie

Trial in Progress: PROSERA, a Phase 3 Study of the Efficacy and Safety of Seralutinib in Adults with Pulmonary Arterial Hypertension (PAH)

2025 · M Held, O Sitbon, et al. · Pneumologie

TORREY Phase 2 Study of Seralutinib in Pulmonary Arterial Hypertension (PAH): Circulating Biomarkers of Proliferation, Inflammation and Fibrosis Improve with Treatment

2025 · H Ghofrani, R Osterhout, et al. · Pneumologie

Effects of inhaled seralutinib on right ventricular-pulmonary arterial (RV-PA) coupling and right heart function in pulmonary arterial hypertension (PAH)

2023 · R Frantz, K Tello, et al. · European Heart Journal

Works count: 13

Citation count: 581

H-index: 6

I10-index: 5